Long-term sotatercept treatment of pulmonary arterial hypertension: pooled analysis of efficacy and safety
Year: 2026
Type: article
Abstract: Extract Sotatercept is a first-in-class activin-signalling inhibitor approved for treatment of pulmonary arterial hypertension (PAH) [1–3]. SOTERIA ( NCT07218029 ) is a phase III, single-arm, open-label, follow-up study assessing long-term safety, tolerability and efficacy of sotatercept in adults with PAH who participated in a parent sotatercept study [4]. Analysis of pooled data from time of SOTERIA entry through 1 year (mean 15 months) of treatment with sotatercept was previously reported [4]. Here, we provide a novel, more comprehensive and updated analysis of SOTERIA participants from the time of sotatercept initiation (during the parent study or, for those receiving placebo throughout the parent study, at rollover into SOTERIA) up to a median of 2.5 years.
Source: ERJ Open Research
Authors: Ioana R. Preston, Howard M. Julien, David B. Badesch, H. Ardeschir Ghofrani, J. Simon R. Gibbs, Mardi Gomberg-Maitland, Marius M. Hoeper, Vallerie V. McLaughlin, Rogerio Souza, Aaron Waxman, Harald S. Mackenzie, Barry Miller, Yaru Shi, Jianxin Lin, Loïc Perchenet, James Strait, Alexandra G. Cornell, Marc Humbert
Institutions: Lahey Hospital and Medical Center, Lahey Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States), University of Colorado System, University of Colorado Anschutz, Justus-Liebig-Universität Gießen, German Center for Lung Research, Universities of Giessen and Marburg Lung Center, Imperial College London, George Washington University, Medizinische Hochschule Hannover, University of Michigan, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Instituto do Coração - HCFMUSP, Brigham and Women's Hospital, Harvard University, Inserm, Université Paris-Saclay, Assistance Publique – Hôpitaux de Paris, Bicêtre Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $808
OpenAlex ID: W7225860665
